Blog
RSS FeedPosted by Michael Wonder on 15 Mar 2022
Better care and treatment for Australians with blood cancer
15 March 2022 - Australians with blood cancer will receive improved treatment and care through new and continued funding from the ...
Posted by Michael Wonder on 02 Mar 2022
BeiGene hits major milestone with first PBS approved cancer treatment
1 March 2022 - BeiGene is welcoming the listing of Brukinsa (zanubrutinib), a targeted treatment for mantle cell lymphoma, an aggressive ...
Posted by Michael Wonder on 26 Feb 2022
Landmark PBS listing for Australians with leukaemia
25 February 2022 - From 1 March 2022, Australians with acute myeloid leukaemia will have access to a new treatment option ...
Posted by Michael Wonder on 25 Feb 2022
MAP offers new online pathway for accessing cancer treatments
25 February 2022 - Medicines Australia and Rare Cancers Australia yesterday provided pharmaceutical industry stakeholders a preview of a new ...
Posted by Michael Wonder on 19 Feb 2022
Breast cancer drug buying time for terminal women amid push for PBS subsidy
20 February 2022 - Alison Day was given just months to live after being diagnosed with stage four terminal breast cancer ...
Posted by Michael Wonder on 14 Feb 2022
Peter paid $60,000 to boost his cancer survival chances, but others miss out
15 February 2022 - Some cancer patients are dipping into their superannuation to pay for treatments under a “two-tiered system” ...
Posted by Michael Wonder on 31 Jan 2022
Schedule of Pharmaceutical Benefits - 1 February 2022 update
1 February 2022 - The February 2022 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 30 Jan 2022
PBS listing to benefit Australians with rare type of non-Hodgkin lymphoma
31 January 2022 - From 1 February, thousands of Australians with a relapsed and/or refractory mantle cell lymphoma, a form of ...
Posted by Michael Wonder on 30 Dec 2021
PBS listing for Braftovi and cetuximab for metastatic bowel cancer patients with BRAFV600 mutation
30 December 2021 - Pierre Fabre Australia today announced that Braftovi (encorafenib) in combination with cetuximab will be listed on the ...
Posted by Michael Wonder on 17 Dec 2021
Medicine agency recommends listing of life-saving drugs for Australian men with deadly forms of prostate cancer
17 December 2021 - Prostate Cancer Foundation of Australia has welcomed recommendations by Australia’s Pharmaceutical Benefits Advisory Committee to list ...
Posted by Michael Wonder on 28 Nov 2021
New treatment for Australians with leukaemia
28 November 2021 - From 1 December 2021, Australians with acute myeloid leukaemia will have access to a new treatment option ...
Posted by Michael Wonder on 15 Nov 2021
Supporting Australians with rare stomach and bowel cancer
15 November 2021 - The Morrison Government will list Qinlock (ripretinib) on the PBS for the treatment of advanced gastro-intestinal stromal ...
Posted by Michael Wonder on 14 Nov 2021
Rare cancer drug to be subsidised
14 November 2021 - A drug to treat a rare stomach and bowel cancer will be subsidised after being listed ...
Posted by Michael Wonder on 01 Nov 2021
Australia to subsidise multiple myeloma drug Darzalex under PBS
31 October 2021 - Blood cancer patients will be among those to benefit with better access to medicine under the Pharmaceutical ...
Posted by Michael Wonder on 31 Oct 2021
Prostate cancer treatment to be put on PBS
31 October 2021 - For the first time in seven years, a prostate cancer therapy will be added to the ...